LONDON (Alliance News) - Silence Therapeutics PLC Tuesday said it raised gross proceeds of GBP11.4 million in a share placing. The group had said on Monday that it was looking to raise funds in a placing with new and existing institutional investors, and certain participating direct Read More

Silence Therapeutics Announces Plans To Raise GBP10 Million

28th Apr 2014 16:40

LONDON (Alliance News) - Silence Therapeutics PLC Monday announced a share issuance to raise a minimum of GBP10 million. The group said it will raise the share placing with new and existing institutional investors, and certain participating directors will be conducted by way of an accelerat Read More

Silence Therapeutics Expands RNA Delivery System To Multiple Tissues

28th Apr 2014 11:51

LONDON (Alliance News) - Silence Therapeutics PLC said Monday that it had successfully translated data from trials with rodents of its Ribonucleic acid lung delivery system DACC to non-human primates, showing it can deliver Ribonucleic acid to multiple tissues. Ribonucleic acid is a family Read More

Silence Therapeutics Narrows Losses; Considers Equity Fundraising

19th Mar 2014 13:39

LONDON (Alliance News) - Shares in Silence Therapeutics PLC dropped Wednesday after the biotechnology company said it narrowed its losses in 2013, but is considering a potential equity fundraising for further working capital. The group said it currently holds net cash of GBP18.9 million, al Read More

UK MORNING BRIEFING: Antofagasta, Smiths Group Weigh On FTSE 100

19th Mar 2014 08:35

LONDON (Alliance News) -Shares have opened mostly flat Wednesday ahead of UK jobs figures and budget statement. Shares of FTSE 100 engineering firm Smiths Group were down 4.0% at the open, as it reported lower pretax profit due to the company's Medical and Defence b Read More

Silence Therapeutics Says Progress Made On Programmes in 2013

27th Feb 2014 14:03

LONDON (Alliance News) - Silence Therapeutics PLC said Thursday that it had made progress in both its pre clinic and clinical programmes during 2013, in a year end trading update. Silence said that patient enrollment for its Phase IIa trial in pancreatic cancer is progressing, and it expect Read More

Value8,809.74

Change53.53